Obseva SA - ESG Rating & Company Profile powered by AI
The assessment of Obseva SA employs data from across the internet as well as from available filings by Obseva SA. The ESG score for Obseva SA represents its reporting of the UN Sustainable Development Goals. Full ESG analysis of Obseva SA are reached by signing in.
Obseva SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.5; made up of an environmental score of 2.0, social score of 8.0 and governance score of 3.4.
4.5
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1199 | Tianda Pharmaceuticals Ltd | 4.6 | High |
| 1199 | Zai Lab Ltd | 4.6 | High |
| 1252 | Obseva SA | 4.5 | High |
| 1252 | Amicus Therapeutics Inc | 4.5 | High |
| 1252 | Akebia Therapeutics Inc | 4.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Obseva SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Obseva SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Obseva SA report the average age of the workforce?
Sign up for free to unlockDoes Obseva SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Obseva SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Obseva SA disclose cybersecurity risks?
Sign up for free to unlockDoes Obseva SA offer flexible work?
Sign up for free to unlockDoes Obseva SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Obseva SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Obseva SA conduct supply chain audits?
Sign up for free to unlockDoes Obseva SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Obseva SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Obseva SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Obseva SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Obseva SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Obseva SA disclose water use targets?
Sign up for free to unlockDoes Obseva SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Obseva SA have a product recall in the last two years?
Sign up for free to unlockDoes Obseva SA disclose incidents of discrimination?
Sign up for free to unlockDoes Obseva SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Obseva SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Obseva SA disclose parental leave metrics?
Sign up for free to unlockDoes Obseva SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Obseva SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Obseva SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Obseva SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Obseva SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Obseva SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Obseva SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Obseva SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Obseva SA disclose its waste policy?
Sign up for free to unlockDoes Obseva SA report according to TCFD requirements?
Sign up for free to unlockDoes Obseva SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Obseva SA disclose energy use targets?
Sign up for free to unlockDoes Obseva SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Obseva SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Obseva SA
These potential risks are based on the size, segment and geographies of the company.
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.